search
Back to results

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

Primary Purpose

Opioid Use Disorder

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
CVL-354
[11C]-LY2795050
[11C]-carfentanil
Sponsored by
Cerevel Therapeutics, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Opioid Use Disorder focused on measuring Healthy adult participants

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Women of nonchildbearing potential and men 18 to 55 years, inclusive, at the time of signing the informed consent form (ICF).
  2. Healthy as determined by medical evaluation, including medical and psychiatric history, physical and neurological examinations, ECG, vital sign measurements, and laboratory test results, as evaluated by the investigator.
  3. Body mass index of 18.5 to 32.0 kilograms per square meter (kg/m^2), inclusive, and total body weight >50 kg (110 pounds [lb]) at Screening.
  4. Sexually active men with a pregnant or nonpregnant partner of childbearing potential must agree to comply with the following contraception requirements during the trial and for 7 days after the last dose of investigational medicinal product (IMP):

    • Use condom or remain abstinent. In addition, male participants should not donate sperm for a minimum of 7 days following the last dose of IMP.

  5. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  6. Ability, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures.

Exclusion Criteria:

  1. Current or past history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus), malignancy (except for basal cell carcinoma of the skin and cervical carcinoma in situ, at the discretion of the investigator), hematological, immunological, neurological, or psychiatric disease that, in the opinion of the investigator or medical monitor, could compromise either participant safety or the results of the trial.
  2. "Yes" responses for any of the following items on the C-SSRS (within the individual's lifetime):

    • Suicidal Ideation Item 3 (Active Suicidal Ideation with Any Methods [Not Plan] without Intent to Act)
    • Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan)
    • Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent)
    • Any of the Suicidal Behavior items (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior) "Yes" responses for any of the following items on the C-SSRS (within past 12 months):
    • Suicidal Ideation Item 1 (Wish to be Dead)
    • Suicidal Ideation Item 2 (Non-Specific Active Suicidal Thoughts) Serious risk of suicide in the opinion of the investigator is also exclusionary.
  3. History of substance or alcohol-use disorder (excluding nicotine or caffeine) as per Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria within 12 months prior to signing the ICF.
  4. Any condition or surgery that could possibly affect drug absorption, including, but not limited to, bowel resections, bariatric weight loss surgery/procedures, gastrectomy, uncomplicated appendectomy, and cholecystectomy.
  5. Receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination or booster within 7 days of planned dosing. In addition, participants who plan to receive SARS-CoV-2 vaccination or booster while participating in the trial or for a minimum of 7 days (to cover at least 5 half-lives of IMP) after the last dose of IMP will be excluded.
  6. Have recently been diagnosed with symptomatic coronavirus disease-2019 (COVID-19) or test positive (i.e., using polymerase chain reaction (PCR) or rapid antigen test) for COVID-19 within 30 days prior to signing the ICF.
  7. Use of prohibited medication prior to randomization or likely to require prohibited concomitant therapy (e.g., prescription and over-the-counter medications, herbal medications, vitamins, and supplements) during the trial.
  8. Positive result for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody with detectable viral ribonucleic acid (RNA) levels at Screening.
  9. Positive drug screen (including cotinine and tetrahydrocannabinol [THC]) or a positive test for alcohol.
  10. Any of the following clinical laboratory test results at the Screening Visit or Check-in (Day -1), which can be confirmed by a single repeat measurement, if deemed necessary:

    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2 × upper limit of normal (ULN).
    • Total bilirubin >1.5 × ULN. If Gilbert's syndrome is suspected, total bilirubin >1.5 × ULN is acceptable if the conjugated or direct bilirubin fraction is <20% of total bilirubin.
  11. Estimated glomerular filtration rate <90 milliliters per minute (mL/min)/1.73 m^2, as calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 equation at the Screening Visit or Check-in (Day -1).

Note: Other protocol-defined Exclusion criteria may apply.

Sites / Locations

  • New Haven, ConnecticutRecruiting
  • Yale PET CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Part A: Kappa Opioid Receptor (KOR) Cohort

Part B: Mu Opioid Receptor (MOR) Cohort

Arm Description

Participants will receive single dose of CVL-354, 25 mg, orally, on Day 1 along with [11C]-LY2795050, intravenous (IV) bolus injection of up to 20 millicurie (mCi) before the baseline and post-dose PET scans. Based on the KOR receptor occupancy (RO) results from this cohort, dosing may be explored further in subsequent cohorts.

Part B will commence after Part A cohort is completed. Participants will receive single dose of CVL-354 150 mg, orally, on Day 1 along with [11C]-carfentanil, IV bolus injection of up to 20 mCi before the baseline and post-dose PET scans. Based on the MOR RO results from this cohort, dosing may be explored further in subsequent cohorts.

Outcomes

Primary Outcome Measures

Kappa Opioid Receptor Occupancy in the Brain Following Single Oral Doses of CVL-354 in Healthy Adult Participants
Mu Opioid Receptor Occupancy in the Brain Following Single Oral Doses of CVL-354 in Healthy Adult Participants

Secondary Outcome Measures

Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Results
Number of Participants With Clinically Significant Changes in Vital Sign Measurements
Number of Participants Clinically Significant Changes in Clinical Laboratory Assessments
Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results
Number of Participants With Suicidal Ideation and Behavior Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)
The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.
Maximum Observed Plasma Concentration (Cmax) of CVL-354 During Scan
Area Under the Plasma Concentration-time Curve (AUC) of CVL-354 for Scan Duration
Average Plasma Concentration (Cavg) of CVL-354 for Scan Duration

Full Information

First Posted
September 16, 2022
Last Updated
October 23, 2023
Sponsor
Cerevel Therapeutics, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05547542
Brief Title
Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing
Official Title
A Phase 1, Open-label Trial to Evaluate Target Occupancy of CVL-354 at Kappa Opioid and Mu Opioid Receptors in Brain Following Single Oral Doses in Healthy Participants Using Positron Emission Tomography
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 1, 2023 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cerevel Therapeutics, LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary purpose of this study is to assess the target occupancy at kappa and mu opioid receptors in the brain after single oral doses of CVL-354 in healthy adult participants.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid Use Disorder
Keywords
Healthy adult participants

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part A: Kappa Opioid Receptor (KOR) Cohort
Arm Type
Experimental
Arm Description
Participants will receive single dose of CVL-354, 25 mg, orally, on Day 1 along with [11C]-LY2795050, intravenous (IV) bolus injection of up to 20 millicurie (mCi) before the baseline and post-dose PET scans. Based on the KOR receptor occupancy (RO) results from this cohort, dosing may be explored further in subsequent cohorts.
Arm Title
Part B: Mu Opioid Receptor (MOR) Cohort
Arm Type
Experimental
Arm Description
Part B will commence after Part A cohort is completed. Participants will receive single dose of CVL-354 150 mg, orally, on Day 1 along with [11C]-carfentanil, IV bolus injection of up to 20 mCi before the baseline and post-dose PET scans. Based on the MOR RO results from this cohort, dosing may be explored further in subsequent cohorts.
Intervention Type
Drug
Intervention Name(s)
CVL-354
Intervention Description
Oral solution/capsule
Intervention Type
Drug
Intervention Name(s)
[11C]-LY2795050
Intervention Description
IV injection
Intervention Type
Drug
Intervention Name(s)
[11C]-carfentanil
Intervention Description
IV injection
Primary Outcome Measure Information:
Title
Kappa Opioid Receptor Occupancy in the Brain Following Single Oral Doses of CVL-354 in Healthy Adult Participants
Time Frame
Day 1
Title
Mu Opioid Receptor Occupancy in the Brain Following Single Oral Doses of CVL-354 in Healthy Adult Participants
Time Frame
Day 1
Secondary Outcome Measure Information:
Title
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time Frame
Up to 18 days
Title
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Results
Time Frame
Up to Day 2
Title
Number of Participants With Clinically Significant Changes in Vital Sign Measurements
Time Frame
Up to Day 2
Title
Number of Participants Clinically Significant Changes in Clinical Laboratory Assessments
Time Frame
Up to Day 2
Title
Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results
Time Frame
Up to Day 2
Title
Number of Participants With Suicidal Ideation and Behavior Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)
Description
The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.
Time Frame
Up to Day 2
Title
Maximum Observed Plasma Concentration (Cmax) of CVL-354 During Scan
Time Frame
Day 1 (1.25, 2.0, and 2.75 hours post dose)
Title
Area Under the Plasma Concentration-time Curve (AUC) of CVL-354 for Scan Duration
Time Frame
Day 1 (1.25, 2.0, and 2.75 hours post dose)
Title
Average Plasma Concentration (Cavg) of CVL-354 for Scan Duration
Time Frame
Day 1 (1.25, 2.0, and 2.75 hours post dose)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Women of nonchildbearing potential and men 18 to 55 years, inclusive, at the time of signing the informed consent form (ICF). Healthy as determined by medical evaluation, including medical and psychiatric history, physical and neurological examinations, ECG, vital sign measurements, and laboratory test results, as evaluated by the investigator. Body mass index of 18.5 to 32.0 kilograms per square meter (kg/m^2), inclusive, and total body weight >50 kg (110 pounds [lb]) at Screening. Sexually active men with a pregnant or nonpregnant partner of childbearing potential must agree to comply with the following contraception requirements during the trial and for 7 days after the last dose of investigational medicinal product (IMP): • Use condom or remain abstinent. In addition, male participants should not donate sperm for a minimum of 7 days following the last dose of IMP. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. Ability, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures. Exclusion Criteria: Current or past history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus), malignancy (except for basal cell carcinoma of the skin and cervical carcinoma in situ, at the discretion of the investigator), hematological, immunological, neurological, or psychiatric disease that, in the opinion of the investigator or medical monitor, could compromise either participant safety or the results of the trial. "Yes" responses for any of the following items on the C-SSRS (within the individual's lifetime): Suicidal Ideation Item 3 (Active Suicidal Ideation with Any Methods [Not Plan] without Intent to Act) Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan) Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent) Any of the Suicidal Behavior items (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior) "Yes" responses for any of the following items on the C-SSRS (within past 12 months): Suicidal Ideation Item 1 (Wish to be Dead) Suicidal Ideation Item 2 (Non-Specific Active Suicidal Thoughts) Serious risk of suicide in the opinion of the investigator is also exclusionary. History of substance or alcohol-use disorder (excluding nicotine or caffeine) as per Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria within 12 months prior to signing the ICF. Any condition or surgery that could possibly affect drug absorption, including, but not limited to, bowel resections, bariatric weight loss surgery/procedures, gastrectomy, uncomplicated appendectomy, and cholecystectomy. Receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination or booster within 7 days of planned dosing. In addition, participants who plan to receive SARS-CoV-2 vaccination or booster while participating in the trial or for a minimum of 7 days (to cover at least 5 half-lives of IMP) after the last dose of IMP will be excluded. Have recently been diagnosed with symptomatic coronavirus disease-2019 (COVID-19) or test positive (i.e., using polymerase chain reaction (PCR) or rapid antigen test) for COVID-19 within 30 days prior to signing the ICF. Use of prohibited medication prior to randomization or likely to require prohibited concomitant therapy (e.g., prescription and over-the-counter medications, herbal medications, vitamins, and supplements) during the trial. Positive result for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody with detectable viral ribonucleic acid (RNA) levels at Screening. Positive drug screen (including cotinine and tetrahydrocannabinol [THC]) or a positive test for alcohol. Any of the following clinical laboratory test results at the Screening Visit or Check-in (Day -1), which can be confirmed by a single repeat measurement, if deemed necessary: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2 × upper limit of normal (ULN). Total bilirubin >1.5 × ULN. If Gilbert's syndrome is suspected, total bilirubin >1.5 × ULN is acceptable if the conjugated or direct bilirubin fraction is <20% of total bilirubin. Estimated glomerular filtration rate <90 milliliters per minute (mL/min)/1.73 m^2, as calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 equation at the Screening Visit or Check-in (Day -1). Note: Other protocol-defined Exclusion criteria may apply.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Meenakshi Balakrishnan
Phone
352-474-3136
Email
meenakshi.balakrishnan@iqvia.com
Facility Information:
Facility Name
New Haven, Connecticut
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Individual Site Status
Recruiting
Facility Name
Yale PET Center
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

We'll reach out to this number within 24 hrs